test

A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Conditions

Bladder | Breast - Female | Lung | Pancreas | Stomach

What is the purpose of this trial?

To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 4 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), and small cell lung cancer (SCLC).


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Bristol-Myers Squibb Company
Dates:
02/04/2014
Last Updated:
Study HIC#:
1311013060